(53 days)
No
The document describes image processing and analysis tools but does not mention AI, ML, or related terms like deep learning. The performance studies focus on equivalence to a predicate device rather than validation of an AI/ML model.
No
The device is described as a medical diagnostic system and image processing software, intended to assist physicians with analysis and diagnosis. It does not perform therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that Vitrea is a "medical diagnostic system" and numerous applications within it are intended to "facilitate the extraction and segmentation of user identified aneurysms" and "assist physicians with performing cardiac functional analysis," or a "qualitative and quantitative analysis of coronary arteries" or to "provide image information for diagnosis," which are all diagnostic activities.
Yes
The device description explicitly states it is an "application package developed for use on Vitrea, a medical image processing software," and the intended use describes various software applications for processing and analyzing medical images. There is no mention of accompanying hardware components being part of this specific submission.
Based on the provided text, the Vitrea Software Toshiba Package is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the software is a "medical diagnostic system" and is used as an "adjunct to diagnosis" for various conditions and anatomical sites. This aligns with the definition of an IVD, which is used to provide information for diagnosis.
- Device Description: The description reinforces that it's a "medical image processing software" used to "assist physicians in performing specialized measurements and analysis" based on medical images.
- Input Data: The software processes images acquired from various medical imaging modalities (CT, XA, MR, US), which are data sources used in clinical diagnosis.
While the text doesn't explicitly use the term "In Vitro Diagnostic," the described function and intended use clearly fall under the scope of devices used for diagnostic purposes based on data obtained from the human body.
N/A
Intended Use / Indications for Use
Vitrea Software Toshiba Package is an application package developed for use on Vitrea®, a medical diagnostic system that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. Vitrea has the following additional indications:
The Cerebral Aneurysm Analysis application is intended to facilitate the extraction and segmentation of user identified aneurysms on the cerebral arteries. The software can be used as an adjunct to diagnosis for the purposes of measurement of size and aspect ratio.
The MR Wall Motion Tracking application is intended to assist physicians with performing cardiac functional analysis based upon magnetic resonance images. It provides measurements of global and regional myocardial function that is used for patients with suspected heart disease.
The MR Coronary Tracking application is intended to assist physicians with performing coronary artery analysis for MR heart images which are intended for the qualitative and quantitative analysis of coronary arteries.
The SUREVolume Synthesis application is intended to load volume images acquired by whole-body X-ray CT scanners, X-ray angiography systems, and MRI systems and displays fusion images.
The Angio Viewer application displays image data acquired using an X-ray angiography system. It supports cine display, subtraction, and distance measurement.
The US Cardiac Fusion application enables fusion display of the analysis results obtained using the US 3D Wall Motion Tracking application and the CT Coronary Artery Analysis application.
The Ultrasound Clinical Applications are indicated for the visualization of structures, and dynamic processes with the human body using saved ultrasound DICOM images to provide image information for diagnosis.
Product codes
LLZ
Device Description
Vitrea Software Package, VSTP-001A, an application package developed for use on Vitrea, a medical image processing software, marketed by Vital Images, Inc. Vitrea Software Toshiba Package, VSTP-001A, currently includes seven post processing applications, CT/XA Cerebral Artery Morphological Analysis, MR Wall Motion Tracking, MR Coronary Tracking and Ultrasound Applications Package, which use brain, body or cardiac image data, obtained from CT/XA/MR/US systems, to assist physicians in performing specialized measurements and analysis.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT/XA/MR/US systems, X-ray CT scanners, X-ray angiography systems, MRI systems, ultrasound DICOM images
Anatomical Site
Brain, body, cardiac, cerebral arteries, coronary arteries, whole body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Physicians
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Bench studies were conducted using sample data sets from the predicate device verification activities (K173090) and verifying that the outputs for both devices were substantially the same.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Risk analysis and regression testing was conducted through bench testing are included in this submission which demonstrates that the requirements for the applications have been met. Bench studies were conducted using sample data sets from the predicate device verification activities (K173090) and verifying that the outputs for both devices were substantially the same.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
510(k) Summary
-
- SUBMITTER'S NAME Canon Medical Systems Corporation 1385 Shimoishiqami Otawara-Shi, Tochigi-ken, Japan 324-8550
-
- OFFICIAL CORRESPONDENT Naofumi Watanabe Senior Manager, Regulatory Affairs and Vigilance
-
- ESTABLISHMENT REGISTRATION 9614698
-
- CONTACT PERSON Paul Biggins Director Regulatory Affairs Canon Medical Systems USA, Inc.
-
- DATE PREPARED March 19, 2018
-
- TRADE NAME(S) Vitrea Software Package, VSTP-001A
-
- COMMON NAME Radiological Image Processing Software
-
- DEVICE CLASSIFICATION Class II (per 21 CFR 892.2050, Picture Archiving and Communications System)
9. PRODUCT CODE/DESCRIPTION
90LLZ / Picture Archiving and Communications System
10. PERFORMANCE STANDARD: None
11. PREDICATE DEVICES
| Application | Predicate | 510(k)
Control# | Status |
|---------------------------------------------------------------------------------|--------------------|--------------------|---------|
| MR Wall Motion Tracking | VSTP-001A | K151093 | Cleared |
| Cerebral Aneurysm Analysis
(CT/XA Cerebral Artery
Morphological Analysis) | VSTP-001A | K151093 | Cleared |
| MR Coronary Tracking | VSTP-001A | K171222 | Cleared |
| SUREVolume Synthesis | VSTP-001A1 | K173088 | Cleared |
| Angio Viewer | VSTP-001A | K173088 | Cleared |
| US Cardiac Fusion | VSTP-001A | K173088 | Cleared |
| Ultrasound Application Package | Aplio-i, TUS-i9002 | K173090 | Cleared |
Primary Predicate Device VSTP-001A - K173088
1
2Secondary Predicate Device Aplio-i: TUS-i900 -K173090
12. REASON FOR SUBMISSION
Modification - Porting of application software from a different class device.
13. DEVICE DESCRIPTION
Vitrea Software Package, VSTP-001A, an application package developed for use on Vitrea, a medical image processing software, marketed by Vital Images, Inc. Vitrea Software Toshiba Package, VSTP-001A, currently includes seven post processing applications, CT/XA Cerebral Artery Morphological Analysis, MR Wall Motion Tracking, MR Coronary Tracking and Ultrasound Applications Package, which use brain, body or cardiac image data, obtained from CT/XA/MR/US systems, to assist physicians in performing specialized measurements and analysis.
14. INDICATIONS FOR USE
Vitrea Software Toshiba Package is an application package developed for use on Vitrea®, a medical diagnostic system that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. Vitrea has the following additional indications:
The Cerebral Aneurysm Analysis application is intended to facilitate the extraction and segmentation of user identified aneurysms on the cerebral arteries. The software can be used as an adjunct to diagnosis for the purposes of measurement of size and aspect ratio.
The MR Wall Motion Tracking application is intended to assist physicians with performing cardiac functional analysis based upon magnetic resonance images. It provides measurements of global and regional myocardial function that is used for patients with suspected heart disease.
The MR Coronary Tracking application is intended to assist physicians with performing coronary artery analysis for MR heart images which are intended for the qualitative and quantitative analysis of coronary arteries.
The SUREVolume Synthesis application is intended to load volume images acquired by whole-body X-ray CT scanners, X-ray angiography systems, and MRI systems and displays fusion images.
The Angio Viewer application displays image data acquired using an X-ray angiography system. It supports cine display, subtraction, and distance measurement.
The US Cardiac Fusion application enables fusion display of the analysis results obtained using the US 3D Wall Motion Tracking application and the CT Coronary Artery Analysis application.
The Ultrasound Clinical Applications are indicated for the visualization of structures, and dynamic processes with the human body using saved ultrasound DICOM images to provide image information for diagnosis.
2
SUBSTANTIAL EQUIVALANCE
The software applications included in the Vitrea Software Toshiba Package, VSTP-001A, perform in a manner similar to and are intended for the same use as the predicate devices. The Ultrasound Clinical Applications Package utilizes the same formulas, algorithms and measurements as found on the predicate device. The porting of this software to the Vitrea Workstation required modifications to the GUI and acquiring images from the Vitrea Image Database. The subject and predicated devices are all post processing applications that are used to aid physicians with performing measurement and analysis of diagnotic images.
A complete comparison table is included in this submission. See below for a brief summary of technological characteristics of the devices:
Primary Predicate:
The primary predicate device is the previous version of the device as cleared by PMN 510(k) K173088 The only changes to primary predicate device are the additions of the software that are described below in the secondary predicate device.
| Item | Ultrasound Clinical Application Package
(Subject Device) | Aplio i900 Model TUS-AI900 |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | K173090 | |
| anatomical region | whole body | whole body |
| Main feature | Image processing (Visualization of structure and dynamic processes with the human body to provide image information for diagnosis) | Scanning human body using ultrasound probe
Image Processing (Visualization of structure and dynamic processes with the human body to provide image information for diagnosis) |
| Image data format for image processing | DICOM format of ultrasound image data | Original format of ultrasound image data |
| | - 2D image viewing
- 4D / Cardiac 4D image viewing
- Stress Echo
- Tissue Intensity Analysis
- Time Curve Analysis
- Automated Cardiac flow Measurement
- Cardiac Wall Motion Tracking
- Mitral valve analysis | - 2D image viewing
- 4D / Cardiac 4D image viewing
- Stress Echo
- Tissue Intensity Analysis
- Time Curve Analysis
- Automated Cardiac flow Measurement
- Cardiac Wall Motion Tracking
- Mitral valve analysis |
| | - Vitrea based interface is employed | - Ultrasound System interface is employed. |
Secondary Predicate:
3
15. SAFETY
The device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards. This device is in conformance with the applicable parts of the IEC62304 and IEC62366.
16. TESTING
Risk analysis and regression testing was conducted through bench testing are included in this submission which demonstrates that the requirements for the applications have been met. Bench studies were conducted using sample data sets from the predicate device verification activities (K173090) and verifying that the outputs for both devices were substantially the same.
This device is not subject to Cybersecurity Requirements as it has no access to an outside environment. All images being queued by the VSTP-001A are resident on the host Vitrea platform. The host Vitrea platform conducts all external data transactions and the Cybersecurity documentation is included for the Vitrea.
Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission.
17. CONCLUSION
The software applications included in the Vitrea Software Toshiba Package, VSTP-001A, perform in a manner similar to and are intended for the same use as the predicate device Based upon this information, conformance to standards, successful completion of software validation, application of risk management and design controls and the performance data presented in this submission it is concluded that the subject device is substantially equivalent in safety and effectiveness to the predicate device.
4
Image /page/4/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: on the left, there is a symbol representing the Department of Health & Human Services - USA, and on the right, there is the text "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue. The FDA logo is commonly used to represent the agency's role in regulating and supervising the safety of food, drugs, and other products.
Canon Medical Systems Corporation % Mr. Paul Biggins Director Regulatory Affairs Canon Medical Systems USA., Inc. 2441 Michelle Drive TUSTIN CA 92780
March 30, 2018
Re: K180323
Trade/Device Name: Vitrea Software Package: VSTP-001A Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: January 31, 2018 Received: February 5, 2018
Dear Mr. Biggins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known)
Device Name
Vitrea Software Package; VSTP-001A
Indications for Use (Describe)
Vitrea Software Toshiba Package is an application package developed for use on Vitrea®, a medical diagnostic system that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. Vitrea has the following additional indications:
The Cerebral Aneurysm Analysis application is intended to facilitate the extraction of user identified aneurysms on the cerebral arteries. The software can be used as an adjunct to diagnosis for the purposes of measurement of size and aspect ratio.
The MR Wall Motion Tracking application is intended to assist physicians with performing cardiac functional analysis based upon magnetic resonance images. It provides measurements of global and regional myocardial function that is used for patients with suspected heart disease.
The MR Coronary Tracking application is intended to assist physicians with performing coronary artery analysis for MR heart images which are intended for the qualitative and quantitative analysis of coronary arteries.
The SUREVolume Synthesis application is intended to load volume images acquired by whole-body X-ray CT scanners, X-ray angiography systems, and MRI systems and displays fusion images.
The Angio Viewer application displays image data acquired using an X-ray angiography system. It supports cine display, subtraction, and distance measurement.
The US Cardiac Fusion application enables fusion display of the analysis results obtained using the US 3D Wall Motion Tracking application and the CT Coronary Artery Analysis application.
The Ultrasound Clinical Applications are indication of structures, and dynamic processes with the human body using saved ultrasound DICOM images to provide image information for diagnosis.
Type of Use (Select one or both, as applicable)
| ❌ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------------------------ | ----------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
7
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."